Gabapentin Tablet, Film Coated
Product Images NDC 71610-069

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-069). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610 0069 45

Label for gabapentin 600 mg film-coated tablets by Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, manufacturer information (Sun Pharmaceutical Ind. Ltd., Gujarat, India), and packaging details for 45 tablets. Marked as RX Only with batch number and expiration data visible.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Spl-gabapentin-figure1 (Spl Gabapentin Figure1)

A line graph showing weekly mean pain scores over 8 weeks comparing Gabapentin 3,600 mg/day with placebo in a clinical study. The chart details a 4-week dose titration period followed by a 4-week fixed dose period, indicating a decrease in mean pain scores for Gabapentin and relatively stable scores for placebo.*

FDA Label Image

Spl-gabapentin-figure2 (Spl Gabapentin Figure2)

A line graph showing weekly mean pain scores over 7 weeks, comparing placebo and two dosages of gabapentin (1,800 mg/day and 2,400 mg/day). The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show a decrease in pain scores compared to placebo.*

FDA Label Image

Spl-gabapentin-figure3 (Spl Gabapentin Figure3)

Bar graph showing the proportion of responders with at least 50% reduction in pain score at endpoint in controlled postherpetic neuralgia (PHN) studies. Two studies are compared with placebo (PBO) and gabapentin (GBP) doses indicated. The y-axis represents percentage from 0% to 100%, highlighting differences between treatment groups in each study.*

FDA Label Image

Spl-gabapentin-figure4 (Spl Gabapentin Figure4)

A scatter plot chart illustrating responder rates in patients receiving gabapentin, expressed as percentage differences from placebo across various daily doses (600, 900, 1,200, 1,800 mg). The chart compares three studies (Study a, b, c) with data points showing differences in percentage on the y-axis and daily dose in mg on the x-axis. The chart is labeled as part of adjunctive therapy studies in patients aged 12 years or older with partial seizures.*

FDA Label Image

Spl-gabapentin-formula (Spl Gabapentin Formula)

An illustration of a formula calculating creatinine clearance (CLCr), expressed as a mathematical equation involving age, weight, and serum creatinine, with an adjustment factor for female patients.*

FDA Label Image

Spl-gabapentin-structure (Spl Gabapentin Structure)

Chemical structure of gabapentin, showing a cyclohexane ring with an amino (CH2NH2) and a carboxyl (CH2CO2H) functional group attached.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.